|Bid||0.0000 x 1000|
|Ask||0.0000 x 800|
|Day's Range||0.8400 - 0.9160|
|52 Week Range||0.7800 - 9.2400|
|Beta (3Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.
Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.
Zimmer Biomet (ZBH) prepares for the commercial launch of improvised knee replacement procedures through its flagship program, Persona Revision Knee System.
Shares of Neurotrope Inc. plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's disease (AD) treatment failed to meet the primary endpoint of a phase 2 trial. Trading volume swelled to 4.2 million shares, compared with the full-day average of about 164,000 shares. The stock paced all the decliners on the major U.S. exchanges. The company said the confirmatory study of Bryostatin-1 in moderate to severe AD did not achieve statistical significance in change from baseline to week 13 in the severe impairment battery total score. "We are disappointed in the topline results from the confirmatory Phase 2 study," Chief Executive Charles S. Ryan. "Having just received the data, we are conducting a full review to determine potential next steps and will provide an update of our plans when appropriate." The stock has now lost 90% of its value over the past 12 months, while the iShares Nasdaq Biotechnology ETF has lost 14% and the S&P 500 has gained 3.6%.
(Bloomberg) -- Neurotrope Inc. plunged as much as 82%, falling below a dollar, after a placebo worked better than the company’s experimental treatment for Alzheimer’s disease.Bryostatin-1 showed a 1.3 point improvement on a score judging patients’ mental impairment after three months of treatment while patients getting a placebo treatment had a 2.1 point improvement. The stock fell as low as 81 cents -- a record -- on heavy volume more than 35 times the daily average.“We are disappointed in the topline results from the confirmatory Phase 2 study,” the company’s Chief Executive Officer Charles Ryan said in a statement. “Having just received the data, we are conducting a full review to determine potential next steps.”One of the two analysts tracked by Bloomberg who covers Neurotrope, Maxim’s Jason McCarthy, cut his rating to hold from buy, and removed his $16 price target on the company. He said he was awaiting clarity on if there will be a path forward for bryostatin.Drug developers have been racking up failures in Alzheimer’s as they seek to find a cure for this scourge of aging. Biogen Inc.’s disappointing March results for a drug targeting beta amyloid -- a plaque that builds up in the brain of Alzheimer’s patients -- rocked the market.Drugmakers are persisting nevertheless. Biogen, Eli Lilly & Co., Roche Holding AG as well as small-cap Cassava Sciences Inc. are developing new medicines that target a pathway called tau. Cassava reported its own early results Monday morning, focused on biomarkers of the disease. Cassava’s stock fell 9.3% at 2:25 p.m. The decline could be the result of pressure from Neurotrope’s failure, McCarthy said. Or it could be due to the small size of the study, which included just 13 patients. McCarthy rates Cassava a buy.(Updates to add analyst commentary in fourth and sixth paragraphs)To contact the reporter on this story: Cristin Flanagan in New York at email@example.comTo contact the editors responsible for this story: Catherine Larkin at firstname.lastname@example.org, Jim Silver, Divya BaljiFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Drug developer Neurotrope Inc's shares tumbled nearly 80% on Monday after the company said its experimental treatment for Alzheimer's disease did not meet the main goal of a mid-stage study. Neurotrope said it intends to conduct a complete review of the data to determine next steps in the treatment's development. Alzheimer's disease, which affects parts of the brain that control thought, memory and language, is a progressive condition that could seriously disrupt a patient's ability to carry out daily activities.
It is doubtless a positive to see that the Neurotrope, Inc. (NASDAQ:NTRP) share price has gained some 38% in the last...
Alzheimer’s disease affects some 5.7 million Americans, but biotech company Neurotrope is offering patients new hope with a drug it says shows a “reversal” in the disease. Yahoo Finance’s Alexis Christoforous speaks to Neurotrope CEO Dr. Charles Ryan about his company’s findings.